Jim Cramer's top 10 things to watch in the stock market Friday
Jim Cramer highlights key events for Friday, including Fed Chair Kevin Warsh's speech. Marvell shares fell despite a solid quarter, while Workday beat estimates and saw price target increases. Affirm rose 13% on strong earnings, and Gap Inc. gained 16% after naming a new Old Navy leader. Solstice and Element Solutions abandoned their merger, and Eli Lilly's Mounjaro received FDA approval. Dollar General's price target was raised by Citi and Goldman Sachs.
How this was made
The 30-second read
Why it matters
The mix of earnings beats, price‑target upgrades, and an FDA approval creates short‑term bullish pressure on the highlighted stocks, while merger fallout adds caution for Element Solutions.
Market read
The article aggregates fresh corporate news that could influence short‑term trading decisions across several sectors, offering a snapshot of market catalysts for the day.
What to watch
Potential supply‑chain constraints for data‑center chips and consumer spending pressure could temper gains.
Background
Jim Cramer’s daily watchlist highlights ten US‑listed companies with recent earnings, analyst upgrades, leadership moves, and regulatory events.
Ticker impact
Marvell reported a solid quarter but shares down 7% and announced a new Google partnership.
Short‑term downside risk with potential upside from Google deal.
Results fell short of expectations despite raised forecast, but partnership adds upside potential.
Workday posted top‑ and bottom‑line beats with AI driving over a quarter of new contracts, prompting price‑target hikes.
Likely upside as analysts raise targets.
Earnings beat and AI growth suggest continued momentum.
Affirm delivered a strong quarter, beating operating income and EPS, sending shares up 13% pre‑market.
Further upside expected if momentum holds.
Profitability improvement and strong guidance raise confidence.
Element Solutions shares rose 3% after the company walked away from a $14.5 B merger and saw partner Solstice announce a $500 M buyback.
Modest upside for Element.
Buyback signals confidence, but merger collapse adds uncertainty.
Analyst Jefferies raised Palo Alto Networks price target to $450 ahead of earnings, expecting a beat.
Potential rally pre‑earnings.
Analyst optimism may drive buying ahead of results.
FDA approved Eli Lilly's Mounjaro to reduce cardiovascular risk in adults with type‑2 diabetes.
Long‑term upside for LLY.
Regulatory approval adds a significant revenue stream.
Citi raised Dollar General price target to $135 after a beat‑and‑raise quarter, with Goldman also increasing its target.
Potential upside on improved guidance.
Strong quarter supports target hikes.
Market effects
AI‑driven earnings boost tech sentiment; retail leadership changes lift consumer stocks; FDA approval benefits healthcare.
U.S. equities see modest gains across tech, consumer, and health sectors.
Broad market outlook improves as multiple US issuers report positive news.
Counterpoint
Recent earnings beats may be priced in; further upside could be limited by macro headwinds.
Key entities
- companyMarvell Technology
MRVL – data‑center chip maker reporting solid quarter and Google partnership.
- companyWorkday
WDAY – cloud‑HR software firm beating earnings with AI growth.
- companyAffirm
AFRM – fintech lender delivering strong Q4 results.
- companyEli Lilly
LLY – pharmaceutical company receiving FDA label expansion for Mounjaro.
.jpg%253Ftrim%253D0%252C0%252C0%252C0%2526width%253D1200%2526height%253D800%2526crop%253D1200%253A800&w=3840&q=75)
